drugset / Trial / NCT04906083
Avatrombopag in Patients With End-stage Liver Disease and Thrombocytopenia
Phase 4
Unknown
150 enrolled
Tongji Hospital
Anhui Provincial Hospital · collabTaihe Hospital, Hubei University of Medicine · collabThe First Affiliated Hospital of Nanchang University · collabThe First Hospital of Jilin University · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
End stage liver disease is prone to thrombocytopenia. This study is a multi-center, randomized, prospective, randomized controlled Phase IV Clinical trial to discuss the Efficacy and Safety of Avatrombopag in Patients with End-stage Liver Disease and Thrombocytopenia.
Timeline
- Start
- 2021-02-01
- Primary completion
- 2022-12-31
- Completion
- 2022-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Avatrombopag | Small molecule | 40 mg | — |
| Subject | Avatrombopag | Small molecule | 60 mg | — |
| Background | Ademetionine | Unknown | — | — |
| Background | HEPATOPOIETIN-A | Protein / enzyme biologic | — | — |
| Background | compound glycyrrhizinate | Unknown | — | — |
| Background | reduced glutathione | Unknown | — | — |